Aptevo reports 90% remission rate in frontline AML with mipletamig triplet; no CRS

Aptevo Therapeutics Inc.

9 of 10 frontline AML patients achieved remission with mipletamig + venetoclax + azacitidine across two trials.
RAINIER Cohort 2 fully enrolled; Cohort 3 now open; 5/6 patients in Cohort 1 achieved remission within 30 days.
No cytokine release syndrome observed in ongoing RAINIER trial; favorable safety profile attributed to ADAPTIR format.
Financial results for Q1 2025 reported but no specific figures disclosed in this release.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.